UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the $2 billion takeout and the opportunity in the TCE space. They also assess the drug development landscape for leukodystrophies and the market for biotech IPOs on NASDAQ, where a trio of biotechs exceeded expectation...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioCentury This Week
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
Ep. 367 - FDA, obesity targets and the rise of DACs
Ep. 366 - Europe's need for speed: Bio€quity takeaways
Get summaries like this every morning.
Free AI-powered recaps of BioCentury This Week and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.